Trial Profile
A two part phase IIa trial of PB 1046 fpr treatment of heart failure and cardiomyopathy associated with dystrophinopathies
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Pemziviptadil (Primary)
- Indications Cardiomyopathies; Heart failure
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors PhaseBio Pharmaceuticals
- 07 Dec 2015 New trial record